Crossref
MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS
European Journal of Cancer · 2026-11 · 248 · 117695
DOI: 10.1016/j.ejca.2026.117695 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von A. Maestre und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Maestre, A., Chipón, C., Diaz, F., & López-Muñoz, R. (2026). MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS. European Journal of Cancer, 248, 117695. https://doi.org/10.1016/j.ejca.2026.117695
Vancouver
Maestre A, Chipón C, Diaz F, López-Muñoz R. MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS. European Journal of Cancer. 2026;248:117695. doi:10.1016/j.ejca.2026.117695
BibTeX
@article{Maestre2026,
author = {Maestre, A. and Chipón, C. and Diaz, F. and López-Muñoz, R.},
title = {MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117695},
doi = {10.1016/j.ejca.2026.117695}
}
EUVIMED